Arbutus Biopharma Corp (FRA:I9DN)
€ 3.448 -0.098 (-2.76%) Market Cap: 687.51 Mil Enterprise Value: 558.40 Mil PE Ratio: 0 PB Ratio: 5.95 GF Score: 50/100

Arbutus Biopharma Corp at Chardan Genetic Medicines Conference (Virtual) Transcript

Oct 05, 2021 / 08:30PM GMT
Release Date Price: €3.58 (+0.06%)
Keay Nakae
Chardan Capital Markets - Analyst

It's my pleasure to introduce our next guest from Arbutus Biopharma, President and Chief Executive Officer, William Collier; Chief Scientific Officer, Dr. Mike Sofia; Chief Development Officer, Dr. Gaston Picchio; and Chief Financial Officer, David Hastings. The format for this session is a 25--minute fireside chat. If any of our audience attendees have questions during the session, feel free to type them into the question box under the video player and we'll try to ask them on your behalf.

Questions & Answers

Keay Nakae
Chardan Capital Markets - Analyst

With that, Bill, Mike, Gaston, David, welcome. Well, let's start with you, Bill. Could you please provide a couple of minutes of introductory comments about the state of the business for Arbutus, summarizing your differential approach, and what's been achieved in 2021 year to date?

William Collier
Arbutus Biopharma Corporation - President and CEO

Yes, happy to. Thank you very much, Keay. Just so we can get

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot